캐나다 - 영어 - Health Canada

fresenius biotech gmbh - catumaxomab - solution - 0.1mg - catumaxomab 0.1mg - antineoplastic agents

캐나다 - 영어 - Health Canada

fresenius biotech gmbh - catumaxomab - solution - 0.1mg - catumaxomab 0.1mg - antineoplastic agents

미국 - 영어 - NLM (National Library of Medicine)

genentech, inc. - faricimab (unii: qc4f7fkk7i) (faricimab - unii:qc4f7fkk7i) - vabysmo is a vascular endothelial growth factor (vegf) and angiopoietin 2 (ang-2) inhibitor indicated for the treatment of patients with: vabysmo is contraindicated in patients with ocular or periocular infections. vabysmo is contraindicated in patients with active intraocular inflammation. vabysmo is contraindicated in patients with known hypersensitivity to faricimab or any of the excipients in vabysmo. hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation. risk summary there are no adequate and well-controlled studies of vabysmo administration in pregnant women. administration of vabysmo to pregnant monkeys throughout the period of organogenesis resulted in an increased incidence of abortions at intravenous (iv) doses 158 times the human exposure (based on cmax ) of the maximum recommended human dose [see animal data] . based on the mechanism of action of vegf and ang-2 inhibitors, there is a potential risk to female reproductive capacity, and t

캐나다 - 영어 - Health Canada

amgen canada inc - blinatumomab - powder for solution - 38.5mcg - blinatumomab 38.5mcg - antineoplastic agents

미국 - 영어 - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 300 mg - bupropion hydrochloride extended-release tablets (xl) are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm). the efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with mdd. the efficacy of the sustained-release formulation of bupropion in the maintenance treatment of mdd was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see clinical studies ( 14.1)]. bupropion hydrochloride extended-release tablets (xl) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (sad). the efficacy of bupropion hydrochloride extended-release tablets in the prevention of seasonal major depressive episodes was established in 3

미국 - 영어 - NLM (National Library of Medicine)

remedyrepack inc. - tramadol hydrochloride (unii: 9n7r477wck) (tramadol - unii:39j1lgj30j) - tramadol hydrochloride 200 mg

미국 - 영어 - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - tramadol hydrochloride (unii: 9n7r477wck) (tramadol - unii:39j1lgj30j) - tramadol hydrochloride 200 mg

미국 - 영어 - NLM (National Library of Medicine)

sa3, llc - tramadol hydrochloride (unii: 9n7r477wck) (tramadol - unii:39j1lgj30j) - tramadol hydrochloride 150 mg